Medical Care
Alpha- Antitrypsin Deficiency Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Sep 11, 24
- ID: 546994
- Pages: 126
- Figures: 213
- Views: 3
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
The global market for Alpha- Antitrypsin Deficiency Treatment was estimated to be worth US$ 1860.6 million in 2023 and is forecast to a readjusted size of US$ 3443.4 million by 2030 with a CAGR of 9.0% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Alpha- Antitrypsin Deficiency Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Alpha- Antitrypsin Deficiency Treatment by region & country, by Type, and by Application.
The Alpha- Antitrypsin Deficiency Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alpha- Antitrypsin Deficiency Treatment.
Market Segmentation
By Company
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Segment by Type:
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Segment by Application
Clinic
Hospital
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Alpha- Antitrypsin Deficiency Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Alpha- Antitrypsin Deficiency Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Alpha- Antitrypsin Deficiency Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Alpha- Antitrypsin Deficiency Treatment was estimated to be worth US$ 1860.6 million in 2023 and is forecast to a readjusted size of US$ 3443.4 million by 2030 with a CAGR of 9.0% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Alpha- Antitrypsin Deficiency Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Alpha- Antitrypsin Deficiency Treatment by region & country, by Type, and by Application.
The Alpha- Antitrypsin Deficiency Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alpha- Antitrypsin Deficiency Treatment.
Market Segmentation
By Company
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Segment by Type:
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Segment by Application
Clinic
Hospital
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Alpha- Antitrypsin Deficiency Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Alpha- Antitrypsin Deficiency Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Alpha- Antitrypsin Deficiency Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Alpha- Antitrypsin Deficiency Treatment Product Introduction
1.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast
1.3 Alpha- Antitrypsin Deficiency Treatment Market Trends & Drivers
1.3.1 Alpha- Antitrypsin Deficiency Treatment Industry Trends
1.3.2 Alpha- Antitrypsin Deficiency Treatment Market Drivers & Opportunity
1.3.3 Alpha- Antitrypsin Deficiency Treatment Market Challenges
1.3.4 Alpha- Antitrypsin Deficiency Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Alpha- Antitrypsin Deficiency Treatment Players Revenue Ranking (2023)
2.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue by Company (2019-2024)
2.3 Key Companies Alpha- Antitrypsin Deficiency Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Alpha- Antitrypsin Deficiency Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Alpha- Antitrypsin Deficiency Treatment
2.6 Alpha- Antitrypsin Deficiency Treatment Market Competitive Analysis
2.6.1 Alpha- Antitrypsin Deficiency Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Alpha- Antitrypsin Deficiency Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CT-2009
3.1.2 POL-6014
3.1.3 ARO-AAT
3.1.4 ALNAAT-02
3.1.5 Others
3.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type
3.2.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Alpha- Antitrypsin Deficiency Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Clinic
4.1.2 Hospital
4.1.3 Others
4.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application
4.2.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Alpha- Antitrypsin Deficiency Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region
5.1.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2019-2024)
5.1.3 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2025-2030)
5.1.4 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
5.2.2 North America Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
5.3.2 Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
5.5.2 South America Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value
6.3 United States
6.3.1 United States Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.3.2 United States Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.4.2 Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.5.2 China Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.6.2 Japan Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.7.2 South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.9.2 India Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Adverum Biotechnologies, Inc.
7.1.1 Adverum Biotechnologies, Inc. Profile
7.1.2 Adverum Biotechnologies, Inc. Main Business
7.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.1.4 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Adverum Biotechnologies, Inc. Recent Developments
7.2 Alnylam Pharmaceuticals, Inc.
7.2.1 Alnylam Pharmaceuticals, Inc. Profile
7.2.2 Alnylam Pharmaceuticals, Inc. Main Business
7.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.2.4 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Alnylam Pharmaceuticals, Inc. Recent Developments
7.3 Applied Genetic Technologies Corporation
7.3.1 Applied Genetic Technologies Corporation Profile
7.3.2 Applied Genetic Technologies Corporation Main Business
7.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.3.4 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Arrowhead Pharmaceuticals, Inc. Recent Developments
7.4 Arrowhead Pharmaceuticals, Inc.
7.4.1 Arrowhead Pharmaceuticals, Inc. Profile
7.4.2 Arrowhead Pharmaceuticals, Inc. Main Business
7.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.4.4 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Arrowhead Pharmaceuticals, Inc. Recent Developments
7.5 Carolus Therapeutics, Inc.
7.5.1 Carolus Therapeutics, Inc. Profile
7.5.2 Carolus Therapeutics, Inc. Main Business
7.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.5.4 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Carolus Therapeutics, Inc. Recent Developments
7.6 Cevec Pharmaceuticals GmbH
7.6.1 Cevec Pharmaceuticals GmbH Profile
7.6.2 Cevec Pharmaceuticals GmbH Main Business
7.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.6.4 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Cevec Pharmaceuticals GmbH Recent Developments
7.7 Dicerna Pharmaceuticals, Inc.
7.7.1 Dicerna Pharmaceuticals, Inc. Profile
7.7.2 Dicerna Pharmaceuticals, Inc. Main Business
7.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.7.4 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Dicerna Pharmaceuticals, Inc. Recent Developments
7.8 Digna Biotech, S.L.
7.8.1 Digna Biotech, S.L. Profile
7.8.2 Digna Biotech, S.L. Main Business
7.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.8.4 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Digna Biotech, S.L. Recent Developments
7.9 Editas Medicine, Inc.
7.9.1 Editas Medicine, Inc. Profile
7.9.2 Editas Medicine, Inc. Main Business
7.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.9.4 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Editas Medicine, Inc. Recent Developments
7.10 Grifols, S.A.
7.10.1 Grifols, S.A. Profile
7.10.2 Grifols, S.A. Main Business
7.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.10.4 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Grifols, S.A. Recent Developments
7.11 Inhibrx
7.11.1 Inhibrx Profile
7.11.2 Inhibrx Main Business
7.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.11.4 Inhibrx Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 Inhibrx Recent Developments
7.12 Intellia Therapeutics, Inc.
7.12.1 Intellia Therapeutics, Inc. Profile
7.12.2 Intellia Therapeutics, Inc. Main Business
7.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.12.4 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Intellia Therapeutics, Inc. Recent Developments
7.13 International Stem Cell Corporation
7.13.1 International Stem Cell Corporation Profile
7.13.2 International Stem Cell Corporation Main Business
7.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.13.4 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 International Stem Cell Corporation Recent Developments
7.14 Ionis Pharmaceuticals, Inc.
7.14.1 Ionis Pharmaceuticals, Inc. Profile
7.14.2 Ionis Pharmaceuticals, Inc. Main Business
7.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.14.4 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.14.5 Ionis Pharmaceuticals, Inc. Recent Developments
7.15 Kamada Ltd.
7.15.1 Kamada Ltd. Profile
7.15.2 Kamada Ltd. Main Business
7.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.15.4 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.15.5 Kamada Ltd. Recent Developments
7.16 Polyphor Ltd.
7.16.1 Polyphor Ltd. Profile
7.16.2 Polyphor Ltd. Main Business
7.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.16.4 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.16.5 Polyphor Ltd. Recent Developments
7.17 ProMetic Life Sciences Inc.
7.17.1 ProMetic Life Sciences Inc. Profile
7.17.2 ProMetic Life Sciences Inc. Main Business
7.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.17.4 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.17.5 ProMetic Life Sciences Inc. Recent Developments
7.18 rEVO Biologics, Inc.
7.18.1 rEVO Biologics, Inc. Profile
7.18.2 rEVO Biologics, Inc. Main Business
7.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.18.4 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.18.5 rEVO Biologics, Inc. Recent Developments
7.19 Sangamo BioSciences, Inc.
7.19.1 Sangamo BioSciences, Inc. Profile
7.19.2 Sangamo BioSciences, Inc. Main Business
7.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.19.4 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.19.5 Sangamo BioSciences, Inc. Recent Developments
8 Industry Chain Analysis
8.1 Alpha- Antitrypsin Deficiency Treatment Industrial Chain
8.2 Alpha- Antitrypsin Deficiency Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Alpha- Antitrypsin Deficiency Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Alpha- Antitrypsin Deficiency Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Alpha- Antitrypsin Deficiency Treatment Product Introduction
1.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast
1.3 Alpha- Antitrypsin Deficiency Treatment Market Trends & Drivers
1.3.1 Alpha- Antitrypsin Deficiency Treatment Industry Trends
1.3.2 Alpha- Antitrypsin Deficiency Treatment Market Drivers & Opportunity
1.3.3 Alpha- Antitrypsin Deficiency Treatment Market Challenges
1.3.4 Alpha- Antitrypsin Deficiency Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Alpha- Antitrypsin Deficiency Treatment Players Revenue Ranking (2023)
2.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue by Company (2019-2024)
2.3 Key Companies Alpha- Antitrypsin Deficiency Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Alpha- Antitrypsin Deficiency Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Alpha- Antitrypsin Deficiency Treatment
2.6 Alpha- Antitrypsin Deficiency Treatment Market Competitive Analysis
2.6.1 Alpha- Antitrypsin Deficiency Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Alpha- Antitrypsin Deficiency Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CT-2009
3.1.2 POL-6014
3.1.3 ARO-AAT
3.1.4 ALNAAT-02
3.1.5 Others
3.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type
3.2.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Alpha- Antitrypsin Deficiency Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Clinic
4.1.2 Hospital
4.1.3 Others
4.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application
4.2.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Alpha- Antitrypsin Deficiency Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region
5.1.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2019-2024)
5.1.3 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2025-2030)
5.1.4 Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
5.2.2 North America Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
5.3.2 Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
5.5.2 South America Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value
6.3 United States
6.3.1 United States Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.3.2 United States Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.4.2 Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.5.2 China Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.6.2 Japan Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.7.2 South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019-2030
6.9.2 India Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Alpha- Antitrypsin Deficiency Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Adverum Biotechnologies, Inc.
7.1.1 Adverum Biotechnologies, Inc. Profile
7.1.2 Adverum Biotechnologies, Inc. Main Business
7.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.1.4 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Adverum Biotechnologies, Inc. Recent Developments
7.2 Alnylam Pharmaceuticals, Inc.
7.2.1 Alnylam Pharmaceuticals, Inc. Profile
7.2.2 Alnylam Pharmaceuticals, Inc. Main Business
7.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.2.4 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Alnylam Pharmaceuticals, Inc. Recent Developments
7.3 Applied Genetic Technologies Corporation
7.3.1 Applied Genetic Technologies Corporation Profile
7.3.2 Applied Genetic Technologies Corporation Main Business
7.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.3.4 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Arrowhead Pharmaceuticals, Inc. Recent Developments
7.4 Arrowhead Pharmaceuticals, Inc.
7.4.1 Arrowhead Pharmaceuticals, Inc. Profile
7.4.2 Arrowhead Pharmaceuticals, Inc. Main Business
7.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.4.4 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Arrowhead Pharmaceuticals, Inc. Recent Developments
7.5 Carolus Therapeutics, Inc.
7.5.1 Carolus Therapeutics, Inc. Profile
7.5.2 Carolus Therapeutics, Inc. Main Business
7.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.5.4 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Carolus Therapeutics, Inc. Recent Developments
7.6 Cevec Pharmaceuticals GmbH
7.6.1 Cevec Pharmaceuticals GmbH Profile
7.6.2 Cevec Pharmaceuticals GmbH Main Business
7.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.6.4 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Cevec Pharmaceuticals GmbH Recent Developments
7.7 Dicerna Pharmaceuticals, Inc.
7.7.1 Dicerna Pharmaceuticals, Inc. Profile
7.7.2 Dicerna Pharmaceuticals, Inc. Main Business
7.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.7.4 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Dicerna Pharmaceuticals, Inc. Recent Developments
7.8 Digna Biotech, S.L.
7.8.1 Digna Biotech, S.L. Profile
7.8.2 Digna Biotech, S.L. Main Business
7.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.8.4 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Digna Biotech, S.L. Recent Developments
7.9 Editas Medicine, Inc.
7.9.1 Editas Medicine, Inc. Profile
7.9.2 Editas Medicine, Inc. Main Business
7.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.9.4 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Editas Medicine, Inc. Recent Developments
7.10 Grifols, S.A.
7.10.1 Grifols, S.A. Profile
7.10.2 Grifols, S.A. Main Business
7.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.10.4 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Grifols, S.A. Recent Developments
7.11 Inhibrx
7.11.1 Inhibrx Profile
7.11.2 Inhibrx Main Business
7.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.11.4 Inhibrx Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 Inhibrx Recent Developments
7.12 Intellia Therapeutics, Inc.
7.12.1 Intellia Therapeutics, Inc. Profile
7.12.2 Intellia Therapeutics, Inc. Main Business
7.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.12.4 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Intellia Therapeutics, Inc. Recent Developments
7.13 International Stem Cell Corporation
7.13.1 International Stem Cell Corporation Profile
7.13.2 International Stem Cell Corporation Main Business
7.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.13.4 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 International Stem Cell Corporation Recent Developments
7.14 Ionis Pharmaceuticals, Inc.
7.14.1 Ionis Pharmaceuticals, Inc. Profile
7.14.2 Ionis Pharmaceuticals, Inc. Main Business
7.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.14.4 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.14.5 Ionis Pharmaceuticals, Inc. Recent Developments
7.15 Kamada Ltd.
7.15.1 Kamada Ltd. Profile
7.15.2 Kamada Ltd. Main Business
7.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.15.4 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.15.5 Kamada Ltd. Recent Developments
7.16 Polyphor Ltd.
7.16.1 Polyphor Ltd. Profile
7.16.2 Polyphor Ltd. Main Business
7.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.16.4 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.16.5 Polyphor Ltd. Recent Developments
7.17 ProMetic Life Sciences Inc.
7.17.1 ProMetic Life Sciences Inc. Profile
7.17.2 ProMetic Life Sciences Inc. Main Business
7.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.17.4 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.17.5 ProMetic Life Sciences Inc. Recent Developments
7.18 rEVO Biologics, Inc.
7.18.1 rEVO Biologics, Inc. Profile
7.18.2 rEVO Biologics, Inc. Main Business
7.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.18.4 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.18.5 rEVO Biologics, Inc. Recent Developments
7.19 Sangamo BioSciences, Inc.
7.19.1 Sangamo BioSciences, Inc. Profile
7.19.2 Sangamo BioSciences, Inc. Main Business
7.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
7.19.4 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2019-2024)
7.19.5 Sangamo BioSciences, Inc. Recent Developments
8 Industry Chain Analysis
8.1 Alpha- Antitrypsin Deficiency Treatment Industrial Chain
8.2 Alpha- Antitrypsin Deficiency Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Alpha- Antitrypsin Deficiency Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Alpha- Antitrypsin Deficiency Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Alpha- Antitrypsin Deficiency Treatment Market Trends
Table 2. Alpha- Antitrypsin Deficiency Treatment Market Drivers & Opportunity
Table 3. Alpha- Antitrypsin Deficiency Treatment Market Challenges
Table 4. Alpha- Antitrypsin Deficiency Treatment Market Restraints
Table 5. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Alpha- Antitrypsin Deficiency Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Alpha- Antitrypsin Deficiency Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Alpha- Antitrypsin Deficiency Treatment
Table 10. Global Alpha- Antitrypsin Deficiency Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Adverum Biotechnologies, Inc. Basic Information List
Table 32. Adverum Biotechnologies, Inc. Description and Business Overview
Table 33. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Adverum Biotechnologies, Inc. (2019-2024)
Table 35. Adverum Biotechnologies, Inc. Recent Developments
Table 36. Alnylam Pharmaceuticals, Inc. Basic Information List
Table 37. Alnylam Pharmaceuticals, Inc. Description and Business Overview
Table 38. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Alnylam Pharmaceuticals, Inc. (2019-2024)
Table 40. Alnylam Pharmaceuticals, Inc. Recent Developments
Table 41. Applied Genetic Technologies Corporation Basic Information List
Table 42. Applied Genetic Technologies Corporation Description and Business Overview
Table 43. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Applied Genetic Technologies Corporation (2019-2024)
Table 45. Applied Genetic Technologies Corporation Recent Developments
Table 46. Arrowhead Pharmaceuticals, Inc. Basic Information List
Table 47. Arrowhead Pharmaceuticals, Inc. Description and Business Overview
Table 48. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Arrowhead Pharmaceuticals, Inc. (2019-2024)
Table 50. Arrowhead Pharmaceuticals, Inc. Recent Developments
Table 51. Carolus Therapeutics, Inc. Basic Information List
Table 52. Carolus Therapeutics, Inc. Description and Business Overview
Table 53. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Carolus Therapeutics, Inc. (2019-2024)
Table 55. Carolus Therapeutics, Inc. Recent Developments
Table 56. Cevec Pharmaceuticals GmbH Basic Information List
Table 57. Cevec Pharmaceuticals GmbH Description and Business Overview
Table 58. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Cevec Pharmaceuticals GmbH (2019-2024)
Table 60. Cevec Pharmaceuticals GmbH Recent Developments
Table 61. Dicerna Pharmaceuticals, Inc. Basic Information List
Table 62. Dicerna Pharmaceuticals, Inc. Description and Business Overview
Table 63. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Dicerna Pharmaceuticals, Inc. (2019-2024)
Table 65. Dicerna Pharmaceuticals, Inc. Recent Developments
Table 66. Digna Biotech, S.L. Basic Information List
Table 67. Digna Biotech, S.L. Description and Business Overview
Table 68. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Digna Biotech, S.L. (2019-2024)
Table 70. Digna Biotech, S.L. Recent Developments
Table 71. Editas Medicine, Inc. Basic Information List
Table 72. Editas Medicine, Inc. Description and Business Overview
Table 73. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Editas Medicine, Inc. (2019-2024)
Table 75. Editas Medicine, Inc. Recent Developments
Table 76. Grifols, S.A. Basic Information List
Table 77. Grifols, S.A. Description and Business Overview
Table 78. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Grifols, S.A. (2019-2024)
Table 80. Grifols, S.A. Recent Developments
Table 81. Inhibrx Basic Information List
Table 82. Inhibrx Description and Business Overview
Table 83. Inhibrx Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Inhibrx (2019-2024)
Table 85. Inhibrx Recent Developments
Table 86. Intellia Therapeutics, Inc. Basic Information List
Table 87. Intellia Therapeutics, Inc. Description and Business Overview
Table 88. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 89. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Intellia Therapeutics, Inc. (2019-2024)
Table 90. Intellia Therapeutics, Inc. Recent Developments
Table 91. International Stem Cell Corporation Basic Information List
Table 92. International Stem Cell Corporation Description and Business Overview
Table 93. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 94. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of International Stem Cell Corporation (2019-2024)
Table 95. International Stem Cell Corporation Recent Developments
Table 96. Ionis Pharmaceuticals, Inc. Basic Information List
Table 97. Ionis Pharmaceuticals, Inc. Description and Business Overview
Table 98. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 99. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Ionis Pharmaceuticals, Inc. (2019-2024)
Table 100. Ionis Pharmaceuticals, Inc. Recent Developments
Table 101. Kamada Ltd. Basic Information List
Table 102. Kamada Ltd. Description and Business Overview
Table 103. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 104. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Kamada Ltd. (2019-2024)
Table 105. Kamada Ltd. Recent Developments
Table 106. Polyphor Ltd. Basic Information List
Table 107. Polyphor Ltd. Description and Business Overview
Table 108. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 109. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Polyphor Ltd. (2019-2024)
Table 110. Polyphor Ltd. Recent Developments
Table 111. ProMetic Life Sciences Inc. Basic Information List
Table 112. ProMetic Life Sciences Inc. Description and Business Overview
Table 113. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 114. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of ProMetic Life Sciences Inc. (2019-2024)
Table 115. ProMetic Life Sciences Inc. Recent Developments
Table 116. rEVO Biologics, Inc. Basic Information List
Table 117. rEVO Biologics, Inc. Description and Business Overview
Table 118. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 119. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of rEVO Biologics, Inc. (2019-2024)
Table 120. rEVO Biologics, Inc. Recent Developments
Table 121. Sangamo BioSciences, Inc. Basic Information List
Table 122. Sangamo BioSciences, Inc. Description and Business Overview
Table 123. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 124. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Sangamo BioSciences, Inc. (2019-2024)
Table 125. Sangamo BioSciences, Inc. Recent Developments
Table 126. Key Raw Materials Lists
Table 127. Raw Materials Key Suppliers Lists
Table 128. Alpha- Antitrypsin Deficiency Treatment Downstream Customers
Table 129. Alpha- Antitrypsin Deficiency Treatment Distributors List
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
Table 133. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Alpha- Antitrypsin Deficiency Treatment Product Picture
Figure 2. Global Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Alpha- Antitrypsin Deficiency Treatment Report Years Considered
Figure 5. Global Alpha- Antitrypsin Deficiency Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Alpha- Antitrypsin Deficiency Treatment Revenue in 2023
Figure 7. Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. CT-2009 Picture
Figure 9. POL-6014 Picture
Figure 10. ARO-AAT Picture
Figure 11. ALNAAT-02 Picture
Figure 12. Others Picture
Figure 13. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Alpha- Antitrypsin Deficiency Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 15. Product Picture of Clinic
Figure 16. Product Picture of Hospital
Figure 17. Product Picture of Others
Figure 18. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Alpha- Antitrypsin Deficiency Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value (%), (2019-2030)
Figure 31. United States Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 37. China Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 39. China Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 49. India Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 51. India Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 52. Alpha- Antitrypsin Deficiency Treatment Industrial Chain
Figure 53. Alpha- Antitrypsin Deficiency Treatment Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Table 1. Alpha- Antitrypsin Deficiency Treatment Market Trends
Table 2. Alpha- Antitrypsin Deficiency Treatment Market Drivers & Opportunity
Table 3. Alpha- Antitrypsin Deficiency Treatment Market Challenges
Table 4. Alpha- Antitrypsin Deficiency Treatment Market Restraints
Table 5. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Alpha- Antitrypsin Deficiency Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Alpha- Antitrypsin Deficiency Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Alpha- Antitrypsin Deficiency Treatment
Table 10. Global Alpha- Antitrypsin Deficiency Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Adverum Biotechnologies, Inc. Basic Information List
Table 32. Adverum Biotechnologies, Inc. Description and Business Overview
Table 33. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Adverum Biotechnologies, Inc. (2019-2024)
Table 35. Adverum Biotechnologies, Inc. Recent Developments
Table 36. Alnylam Pharmaceuticals, Inc. Basic Information List
Table 37. Alnylam Pharmaceuticals, Inc. Description and Business Overview
Table 38. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Alnylam Pharmaceuticals, Inc. (2019-2024)
Table 40. Alnylam Pharmaceuticals, Inc. Recent Developments
Table 41. Applied Genetic Technologies Corporation Basic Information List
Table 42. Applied Genetic Technologies Corporation Description and Business Overview
Table 43. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Applied Genetic Technologies Corporation (2019-2024)
Table 45. Applied Genetic Technologies Corporation Recent Developments
Table 46. Arrowhead Pharmaceuticals, Inc. Basic Information List
Table 47. Arrowhead Pharmaceuticals, Inc. Description and Business Overview
Table 48. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Arrowhead Pharmaceuticals, Inc. (2019-2024)
Table 50. Arrowhead Pharmaceuticals, Inc. Recent Developments
Table 51. Carolus Therapeutics, Inc. Basic Information List
Table 52. Carolus Therapeutics, Inc. Description and Business Overview
Table 53. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Carolus Therapeutics, Inc. (2019-2024)
Table 55. Carolus Therapeutics, Inc. Recent Developments
Table 56. Cevec Pharmaceuticals GmbH Basic Information List
Table 57. Cevec Pharmaceuticals GmbH Description and Business Overview
Table 58. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Cevec Pharmaceuticals GmbH (2019-2024)
Table 60. Cevec Pharmaceuticals GmbH Recent Developments
Table 61. Dicerna Pharmaceuticals, Inc. Basic Information List
Table 62. Dicerna Pharmaceuticals, Inc. Description and Business Overview
Table 63. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Dicerna Pharmaceuticals, Inc. (2019-2024)
Table 65. Dicerna Pharmaceuticals, Inc. Recent Developments
Table 66. Digna Biotech, S.L. Basic Information List
Table 67. Digna Biotech, S.L. Description and Business Overview
Table 68. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Digna Biotech, S.L. (2019-2024)
Table 70. Digna Biotech, S.L. Recent Developments
Table 71. Editas Medicine, Inc. Basic Information List
Table 72. Editas Medicine, Inc. Description and Business Overview
Table 73. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Editas Medicine, Inc. (2019-2024)
Table 75. Editas Medicine, Inc. Recent Developments
Table 76. Grifols, S.A. Basic Information List
Table 77. Grifols, S.A. Description and Business Overview
Table 78. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Grifols, S.A. (2019-2024)
Table 80. Grifols, S.A. Recent Developments
Table 81. Inhibrx Basic Information List
Table 82. Inhibrx Description and Business Overview
Table 83. Inhibrx Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Inhibrx (2019-2024)
Table 85. Inhibrx Recent Developments
Table 86. Intellia Therapeutics, Inc. Basic Information List
Table 87. Intellia Therapeutics, Inc. Description and Business Overview
Table 88. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 89. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Intellia Therapeutics, Inc. (2019-2024)
Table 90. Intellia Therapeutics, Inc. Recent Developments
Table 91. International Stem Cell Corporation Basic Information List
Table 92. International Stem Cell Corporation Description and Business Overview
Table 93. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 94. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of International Stem Cell Corporation (2019-2024)
Table 95. International Stem Cell Corporation Recent Developments
Table 96. Ionis Pharmaceuticals, Inc. Basic Information List
Table 97. Ionis Pharmaceuticals, Inc. Description and Business Overview
Table 98. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 99. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Ionis Pharmaceuticals, Inc. (2019-2024)
Table 100. Ionis Pharmaceuticals, Inc. Recent Developments
Table 101. Kamada Ltd. Basic Information List
Table 102. Kamada Ltd. Description and Business Overview
Table 103. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 104. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Kamada Ltd. (2019-2024)
Table 105. Kamada Ltd. Recent Developments
Table 106. Polyphor Ltd. Basic Information List
Table 107. Polyphor Ltd. Description and Business Overview
Table 108. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 109. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Polyphor Ltd. (2019-2024)
Table 110. Polyphor Ltd. Recent Developments
Table 111. ProMetic Life Sciences Inc. Basic Information List
Table 112. ProMetic Life Sciences Inc. Description and Business Overview
Table 113. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 114. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of ProMetic Life Sciences Inc. (2019-2024)
Table 115. ProMetic Life Sciences Inc. Recent Developments
Table 116. rEVO Biologics, Inc. Basic Information List
Table 117. rEVO Biologics, Inc. Description and Business Overview
Table 118. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 119. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of rEVO Biologics, Inc. (2019-2024)
Table 120. rEVO Biologics, Inc. Recent Developments
Table 121. Sangamo BioSciences, Inc. Basic Information List
Table 122. Sangamo BioSciences, Inc. Description and Business Overview
Table 123. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Products, Services and Solutions
Table 124. Revenue (US$ Million) in Alpha- Antitrypsin Deficiency Treatment Business of Sangamo BioSciences, Inc. (2019-2024)
Table 125. Sangamo BioSciences, Inc. Recent Developments
Table 126. Key Raw Materials Lists
Table 127. Raw Materials Key Suppliers Lists
Table 128. Alpha- Antitrypsin Deficiency Treatment Downstream Customers
Table 129. Alpha- Antitrypsin Deficiency Treatment Distributors List
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
Table 133. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Alpha- Antitrypsin Deficiency Treatment Product Picture
Figure 2. Global Alpha- Antitrypsin Deficiency Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Alpha- Antitrypsin Deficiency Treatment Report Years Considered
Figure 5. Global Alpha- Antitrypsin Deficiency Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Alpha- Antitrypsin Deficiency Treatment Revenue in 2023
Figure 7. Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. CT-2009 Picture
Figure 9. POL-6014 Picture
Figure 10. ARO-AAT Picture
Figure 11. ALNAAT-02 Picture
Figure 12. Others Picture
Figure 13. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Alpha- Antitrypsin Deficiency Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 15. Product Picture of Clinic
Figure 16. Product Picture of Hospital
Figure 17. Product Picture of Others
Figure 18. Global Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Alpha- Antitrypsin Deficiency Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Alpha- Antitrypsin Deficiency Treatment Sales Value (%), (2019-2030)
Figure 31. United States Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 37. China Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 39. China Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 49. India Alpha- Antitrypsin Deficiency Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Alpha- Antitrypsin Deficiency Treatment Sales Value by Type (%), 2023 VS 2030
Figure 51. India Alpha- Antitrypsin Deficiency Treatment Sales Value by Application (%), 2023 VS 2030
Figure 52. Alpha- Antitrypsin Deficiency Treatment Industrial Chain
Figure 53. Alpha- Antitrypsin Deficiency Treatment Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232